MICU Vicuron Pharmaceuticals (MM)

Vicuron Pharmaceuticals to Present at the 24th Annual SG Cowen Healthcare Conference KING OF PRUSSIA, Pa., March 2 /PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals Inc. announced today that George F. Horner III, President and Chief Executive Officer is scheduled to present a corporate and product update at the 24th Annual SG Cowen Healthcare Conference on Tuesday, March 9, 2004. Mr. Horner will give the corporate update both at 10:15 AM Eastern Time and 11:15 AM Eastern Time at the Boston Marriott Copley Place. To access the live audio broadcast or the subsequent archived recording log on to http://www.vicuron.com/ and click on the investor relations section. Please connect to the website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary. The live broadcast will be archived for 30 days. About Vicuron Vicuron Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing vital medicine for seriously ill patients in North America and Europe. The company recently filed a New Drug Application with the U.S. Food and Drug Administration for its lead product, anidulafungin, a novel antifungal agent. The company's other lead product, dalbavancin, a novel intravenous antibiotic for the treatment of serious Gram-positive infections, is in Phase III clinical trials. Vicuron's versatile research engine integrates industry-leading expertise in functional genomics, natural products discovery, mechanism-based drug design and combinatorial and medicinal chemistry. These approaches are yielding promising novel and next-generation compounds, many of which are in the later stages of preclinical development. In addition, Vicuronhas research and development collaborations with leading pharmaceutical companies, such as Pfizer and Novartis. DATASOURCE: Vicuron Pharmaceuticals Inc. CONTACT: Dov A. Goldstein, M.D. of Vicuron Pharmaceuticals, +1-610-205-2312, ; or E. Blair Schoeb of Burns McClellan, +1-212-213-0006, , for Vicuron Pharmaceuticals Inc.; or Ian R. McConnell of WeissCom Partners, +1-415-362-5018, , for Vicuron Pharmaceuticals Inc. Web site: http://www.vicuron.com/

Copyright